Posted on 2/14/20
Phio Pharmaceuticals Closes $8M Underwritten Public Offering
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced . . .
Posted on 2/13/20
Decision Resources Group Announced as HIDA Industry Data Program Partner
Decision Resources Group (DRG), www.decisionresourcesgroup.com, a premier provider of high-value healthcare data, analytics, and insights products and services to the healthcare industry, has been named as . . .
Posted on 2/13/20
Foundation Medicine and Chugai Announce Partnership with National Cancer Center
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Foundation Medicine, Inc. and Chugai Pharmaceutical, Ltd. (TOKYO: 4519) have entered into an agreement with the National Cancer Center (NCC) for the . . .
Posted on 2/13/20
Syros Announces $60 Million Loan Facility with Oxford Finance
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes
Posted on 2/13/20
Genocea Provides Fourth Quarter 2019 Corporate Update
CAMBRIDGE, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today reported its operating and financial . . .
Posted on 2/13/20
Agios Reports Fourth Quarter and Full Year 2019 Financial Results
CAMBRIDGE, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today reported business highlights and financial results for the fourth quarter and year . . .
Posted on 2/13/20
Is Boston Scientific Stock a Buy?
Boston Scientific (NYSE:BSX) shares are off to a sluggish start this year, down 4.8% so far after climbing 28% in 2019. And the medical device maker's . . .
Posted on 2/13/20
Is Ironwood Pharmaceuticals Stock a Buy?
Ironwood Pharmaceuticals (NASDAQ:IRWD) is coming off a strong year in 2019 when its share price rose more than 53%, well above the 18% investors would have . . .
Posted on 2/13/20
CVS Health Just Beat Expectations and Raised Some
Shares of CVS Health (NYSE:CVS) ticked up on Wednesday morning after the company reported fourth-quarter earnings that exceeded Wall Street expectations and management's own targets.The first . . .
Posted on 2/13/20
RxSense Joins Health Plan Alliance Group Purchasing Organization
BOSTON--(BUSINESS WIRE)--RxSense®, the healthcare technology company, today announced a partnership with the Health Plan Alliance, a nationwide network of health plans and systems, to join its . . .
Posted on 2/13/20
Deciphera Pharmaceuticals Proposes Public Offering of Common Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the commencement of a registered . . .
Posted on 2/13/20
AVROBIO Prices Underwritten Public Offering of $100 Million of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 4,350,000 shares of its . . .
Posted on 2/13/20
Sirtex Medical Announces Collaboration with MIM Software
Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced a collaboration with MIM Software Inc., a leading global provider of practical imaging solutions . . .
Posted on 2/13/20
IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today announced that the Company's Board of Directors has authorized the repurchase of an additional 5.0 million shares of the Company's . . .
Posted on 2/12/20
CVS Health Announces Changes to Support Innovation and Growth
CVS Health (NYSE: CVS) today announced a series of leadership assignments to support the company's continued focus on innovation and strategic growth."We have set a clear . . .
Posted on 2/12/20
LABORIE Medical Technologies Announces Completion of Clinical Innovations Acquisition
LABORIE Medical Technologies, a leading diagnostic and therapeutic medical technology company, today announced it has completed its acquisition
Posted on 2/12/20
Bioprocessing Summit Europe Highlights Innovations in Gene Therapy CMC and Manufacturing
BARCELONA, Spain--(BUSINESS WIRE)--With the global market for gene therapy expected to hit $13 billion (USD) by 2024 (Research And Markets), Bioprocessing Summit Europe is returning March . . .
Posted on 2/12/20
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Biogen (NASDAQ:BIIB) shares surged as much as 32% on Wednesday after the company won a patent challenge to its billion-dollar multiple sclerosis (MS) drug, Tecfidera. The . . .
Posted on 2/12/20
Myomo Prices Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, . . .
Posted on 2/12/20
Elicio Therapeutics and Natera to Collaborate
Elicio Therapeutics, a next generation immuno-oncology company, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced their collaboration in a prospective, . . .
Posted on 2/12/20
Xtelligent Healthcare Media Announces the Launch of PharmaNewsIntelligence
Xtelligent Healthcare Media announces the launch of PharmaNewsIntelligence, a site covering the pharmaceutical, biotechnology, and digital therapeutics industries.PharmaNewsIntelligence marks Xtelligent Healthcare Media's 9th site and solidifies . . .
Posted on 2/12/20
Phio Pharmaceuticals Prices $8M Underwritten Public Offering
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced . . .
Posted on 2/11/20
Beam Therapeutics Announces Closing of Initial Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the closing of its initial public offering of . . .
Posted on 2/11/20
Beam Therapeutics Announces Multiple Scientific Advances in its Base Editing Technology Platforms
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced continued progress in the evolution of its . . .
Posted on 2/11/20
Bristol-Myers Squibb Stock Is Too Cheap to Ignore
Bristol-Myers Squibb's (NYSE:BMY) decision to acquire Celgene in a cash and stock transaction valued at $74 billion wasn't particularly well-received. For instance, one of the company's . . .

